A cysteine trapping assay for risk assessment of reactive acyl CoA metabolites

References

• Bailey MJ, Dickinson RG. 2003. Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact. 145(2):117–137.
   PubMed Web of Science ®Google Scholar
• Brink A, Pähler A, Funk C, Schuler F, Schadt S. 2017. Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discov Today. 22(5):751–756.
   PubMed Web of Science ®Google Scholar
• Chalmers TM, Pohl JEF, Platt DS. 1969. Evaluation in man of fenclozic acid (I.C.I. 54,450:Myalex), a new anti-inflammatory agent. I. Serum concentration studies in healthy individuals and in patients with rheumatoid arthritis. Ann Rheum Dis. 28(6):590–594.
   PubMed Web of Science ®Google Scholar
• Chatfield DH, Tarrant ME, Smith GL, Speirs CF. 1977. Pharmacokinetic studies with benoxaprofen in man: prediction of steady-state levels from single-dose data. Br J Clin Pharmacol. 4(5):579–583.
   PubMed Web of Science ®Google Scholar
• Darnell M, Breitholtz K, Isin EM, Jurva U, Weidolf L. 2015. Significantly different covalent binding of oxidative metabolites, acyl glucuronides, and S-acyl CoA conjugates formed from xenobiotic carboxylic acids in human liver microsomes. Chem Res Toxicol. 28(5):886–896. − 
   PubMed Web of Science ®Google Scholar
• Darnell M, Weidolf L. 2013. Metabolism of xenobiotic carboxylic acids: focus on coenzyme A conjugation, reactivity, and interference with lipid metabolism. Chem Res Toxicol. 26(8):1139–1155.
   PubMed Web of Science ®Google Scholar
• Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. 2000. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos. 28(5):560–566.
   PubMed Web of Science ®Google Scholar
• Gan J, Ruan Q, He B, Zhu M, Shyu WC, Humphreys WG. 2009. In vitro screening of 50 highly prescribed drugs for thiol adduct formation-comparison of potential for drug-induced toxicity and extent of adduct formation. Chem Res Toxicol. 22(4):690–698.
   PubMed Web of Science ®Google Scholar
• Goldkind L, Laine L. 2006. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience. Pharmacoepidemiol Drug Saf. 15(4):213–220.
   PubMed Web of Science ®Google Scholar
• Grillo MP, Benet LZ. 2002. Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. Drug Metab Dispos. 30(1):55–62.
   PubMed Web of Science ®Google Scholar
• Hashizume H, Fukami T, Mishima K, Arakawa H, Mishiro K, Zhang Y, Nakano M, Nakajima M. 2021. Identification of an isoform catalyzing the CoA conjugation of nonsteroidal anti-inflammatory drugs and the evaluation of the expression levels of acyl-CoA synthetases in the human liver. Biochem Pharmacol. 183:114303.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fukuda K, Yoshimura T, Kusano K. 2015. Comparison of the reactivity of trapping reagents toward electrophiles: cysteine derivatives can be bifunctional trapping reagents. Chem Res Toxicol. 28(8):1546–1555.
   PubMed Web of Science ®Google Scholar
• Inoue K, Shibata Y, Takahashi H, Ohe T, Chiba M, Ishii Y. 2009. A trapping method for semi-quantitative assessment of reactive metabolite formation using [35S]cysteine and [14C]cyanide. Drug Metab Pharmacokinet. 24(3):245–254.
   PubMed Web of Science ®Google Scholar
• Kakutani N, Nanayama T, Nomura Y. 2019. Novel risk assessment of reactive metabolites from discovery to clinical stage. J Toxicol Sci. 44(3):201–211.
   PubMed Web of Science ®Google Scholar
• Lassila T, Hokkanen J, Aatsinki SM, Mattila S, Turpeinen M, Tolonen A. 2015. Toxicity of carboxylic acid-containing drugs: the role of acyl migration and CoA conjugation investigated. Chem Res Toxicol. 28(12):2292–2303.
   PubMed Web of Science ®Google Scholar
• Matsuki Y, Fukuhara K, Dan J, Nambara T. 1988. Pharmacokinetic studies of meclomen in human volunteers with single and consecutive oral administrations. Yakubutsudoutai. 3(3):237–249.
   Google Scholar
• Nagatomi H, Yamamoto M, Kuwano S. 1968. Initial plasma concentrations and clinical evaluation of 2,3-nonsteroidal anti-inflammatory drugs (Indomethacin, ibufenac). Japanese J Clin Exp Med. 45:2049–2052.
   Google Scholar
• Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, Leifke E. 2012. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol. 52(7):1007–1016.
   PubMed Web of Science ®Google Scholar
• Nakayama S, Atsumi R, Takakusa H, Kobayashi Y, Kurihara A, Nagai Y, Nakai D, Okazaki O. 2009. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos. 37(9):1970–1977.
   PubMed Web of Science ®Google Scholar
• Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. 2008. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol. 21(9):1814–1822.
   PubMed Web of Science ®Google Scholar
• Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A, Salter R, Simic D, Skaggs H, Singh B, et al. 2018. Fasiglifam (TAK-875): mechanistic investigation and retrospective identification of hazards for drug induced liver injury. Toxicol Sci. 163(2):374–384.
   PubMed Web of Science ®Google Scholar
• Sawamura R, Okudaira N, Watanabe K, Murai T, Kobayashi Y, Tachibana M, Ohnuki T, Masuda K, Honma H, Kurihara A, et al. 2010. Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos. 38(10):1857–1864.
   PubMed Web of Science ®Google Scholar
• Shang J, Tschirret-Guth R, Cancilla M, Samuel K, Chen Q, Chobanian HR, Thomas A, Tong W, Josien H, Buevich AV, et al. 2020. Bioactivation of GPR40 agonist MK-8666: formation of protein adducts in vitro from reactive acyl glucuronide and acyl CoA thioester. Chem Res Toxicol. 33(1):191–201.
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, et al. 2012. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol. 25(8):1616–1632.
   PubMed Web of Science ®Google Scholar
• Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, et al. 2011. Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. Drug Metab Dispos. 39(1):123–131.
   PubMed Web of Science ®Google Scholar